The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
Although the majority of patients with chronic myeloid leukemia do well with treatment with tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many factors that might play a part, including the different BCR-ABL1 transcript types at baseline. The current study w...
| Publicado en: | Cancer (0008543X) Vol. 124; no. 19; pp. 3806 - 3819 |
|---|---|
| Autores principales: | , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |